FibroTouch和声触诊组织量化成像参数评估血吸虫病性肝病患者肝纤维化临床研究*

doi:10.3969/j.issn.1672-5069.2024.06.022

摘要/Abstract

摘要： 目的探讨FibroTouch和超声声触诊组织量化成像(VTQ)参数评估血吸虫病性肝病(SILD)患者肝纤维化的临床价值。方法 2019年2月～2023年2月我院诊治的肝血吸虫病患者58例,均接受病原学和护肝治疗。在治愈后使用FibroTouch行肝脏硬度检测(LSM),使用VTQ检测肝剪切波速度(SWV)。所有患者接受肝活检评估肝纤维化分期,应用ROC分析FibroTouch和VTQ检查参数诊断肝纤维化的效能。结果在58例SILD患者中,肝组织学检查发现S0期7例(12.1%)、S1期15例(25.9%)、S2期16例(27.6%)、S3期12例(20.7%)和S4期8例(13.8%);S4期患者 LSM和SWV分别为(17.4±2.0)kPa和(1.9±0.2)m/s,均显著大于S3期【分别为(15.7±3.4)kPa和(1.7±0.3)m/s,P<0.05】或S2期【分别为(12.4±2.8)kPa和(1.5±0.4)m/s,P<0.05】或S1期【分别为(8.7±2.0)kPa和(1.3±0.3)m/s,P<0.05】或S0期【分别为(5.8±0.9)kPa和(1.1±0.2)m/s,P<0.05】;经ROC分析发现,分别以 LSM=12.8 kPa和SWV=1.5 m/s为截断点,两者联合诊断显著性肝纤维化的曲线下面积(AUC)为0.937,其诊断的敏感度为87.5%,特异度为90.0%,具有较高的诊断效能。结论应用FibroTouch参数LSM和VTQ参数SWV评估SILD患者显著性肝纤维化分期具有一定的临床价值,值得进一步研究。

关键词: 血吸虫病性肝病, 肝纤维化, Fibrotouch, 声触诊组织量化成像, 诊断

Abstract: Objective The aim of this study was to explore clinical efficacy ofFibroTouchand virtual touch tissue quantification (VTQ) parameters in evaluating liver fibrosis in patients with schistosomiasis-induced liver disease (SILD). Methods 58 patients withSILDwere enrolled in our hospital between February 2019 and February 2023, and they all received etiological, liver-protecting and symptomatic supporting treatment. After recovery, FibroTouch was used to detect liver stiffness measurement (LSM), and VTQ was applied to detect liver shear wave velocity (SWV). Liver biopsy was performed to evaluate liver fibrosis staging, and receiver-operating characteristic curve (ROC) was adopted to analyze diagnostic performance of FibroTouch and VTQ parameters in predicting significant liver fibrosis (SLF). Results Of 58 patients with SILD, liver histo-pathological examination showed liver fibrosis S0 stage in 7 cases (12.1%), S1 stage in 15 cases (25.9%), S2 stage in 16 cases (27.6%), S3 stage in 12 cases (20.7%) and S4 stage in 8 cases (13.8%); LSM and SWV in patients with S4 liver fibrosis were (17.4±2.0)kPa and (1.9±0.2)m/s, both significantly greater than [(15.7±3.4)kPa and (1.7±0.3)m/s,P<0.05] in patients with S3 or [(12.4±2.8)kPa and (1.5±0.4)m/s, P<0.05] in those with S2 or [(8.7±2.0)kPa and (1.3±0.3)m/s, P<0.05] in S1 or [(5.8±0.9)kPa and (1.1±0.2)m/s,P<0.05] in S0; ROC analysis showed that AUCwas 0.937, with sensitivity of 87.5% and specificity of 90.0%, when LSM and SWV combination (with 12.8 kPa and 1.5 m/s as cut-off-value, respectivley) in predicting SLF in patients with SILD. Conclusion Combination of LSM and SWV in predicting SLF in patients with SILD really has certain clinical diagnostic efficacy, which might help guide clinicians to make intervention early.

Key words: Schistosomiasis-induced liver disease, Liver fibrosis, FibroTouch, Virtual touch tissue quantification, Diagnosis

唐敏, 曾理, 杨鑫荣. FibroTouch和声触诊组织量化成像参数评估血吸虫病性肝病患者肝纤维化临床研究^*[J]. 实用肝脏病杂志, 2024, 27(6): 887-890.

Tang Min, Zeng Li, Yang Xinrong. FibroTouch and virtual touch tissue quantification parameters in evaluating liver fibrosis in patients with schistosomiasis-induced liver disease[J]. Journal of Practical Hepatology, 2024, 27(6): 887-890.

参考文献

[1] Yang Y, Wang XY, Duan C, et al. Clinicopathological characteristics and its association with digestive system tumors of 1111 patients withSchistosomiasis japonica. Sci Rep, 2023, 13(1):15115.
[2] Wang X, Gong Q, Nie H, et al. High level of C3 is associated with Th2 immune response and liver fibrosis in patients with schistosomiasis. Parasite Immunol, 2024, 46(3):e13029.
[3] 中华医学会肝病学分会. 肝硬化诊治指南.实用肝脏病杂志,2019,22(6):770-792.
[4] 牛志强,李智伟.慢性乙型肝炎肝纤维化无创诊断方法的研究进展.中华传染病杂志2022,40(2):116-120.
[5] Qu Y, Song YY, Chen CW,et al. Diagnostic performance of fibrotouch ultrasound attenuation parameter and liver stiffness measurement in assessing hepatic steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Clin Transl Gastroenterol, 2021, 12(4):e00323.
[6] Bartolotta TV, Randazzo A, Bruno E, et al. Focal liver lesions in cirrhosis: Role of contrast-enhanced ultrasonography. World J Radiol, 2022, 14(4):70-81.
[7] 中华人民共和国卫生部.血吸虫病诊断标准(WS 261-2006).北京:中国标准出版社,2006:1-13.
[8] Bedossa P, Poynard T. An algorithm for grading activity in chronic hepatitis C. Hepatology, 1996, 24(2):289-293.
[9] Gao Y, Zhang X, Jiang T, et al. Inhibition of hepatic natural killer cell function viathe TIGIT receptor in schistosomiasis-induced liver fibrosis. PLoS Pathog, 2023, 19(3):e1011242.
[10] Maggi L, Camelo GMA, Rocha IC, et al. Role of the IL-33/ST2 activation pathway in the development of the hepatic fibrosis induced bySchistosoma mansoni granulomas in mice. Int J Mol Sci, 2023, 24(12):10237.
[11] Hu F, Xie SY, Yuan M, et al. Thedynamics of hepatic fibrosis related to Schistosomiasis and its risk factors in a cohort of China. Pathogens, 2021, 10(12):1532.
[12] Kim D, Cholankeril G, Loomba R, et al. Prevalence of fatty liver disease and fibrosis detected by FibroScan in adults in the United States, 2017-2018. Clin Gastroenterol Hepatol, 2021, 19(7):1499-1501.
[13] Duan WJ, Wang XZ, Ma AL, et al. Multicenter prospective study to validate a new transient elastography device for staging liver fibrosis in patients with chronic hepatitis B. J Dig Dis, 2020, 21(9):519-525.
[14] Yu H, Liu H, Zhang J, et al. Accuracy of FibroTouch in assessing liver steatosis and fibrosis in patients with metabolic-associated fatty liver disease combined with type 2 diabetes mellitus. Ann Palliat Med, 2021, 10(9):9702-9714.
[15] Ozturk A, Olson MC, Samir AE,et al. Liver fibrosis assessment: MR and US elastography. Abdom Radiol (NY), 2022, 47(9):3037-3050.
[16] Dong Y, Koch J, Alhyari A, et al. Ultrasound elastography for characterization of focal liver lesions. Z Gastroenterol, 2023, 61(4):399-410.
[17] 洪叶,牛雪花,沈宇舟,等.FibroTouch联合肝纤维化四项生化指标评估慢性血吸虫病肝病患者肝纤维化程度价值.中国血吸虫病防治杂志,2021,33(6):629-633.
[18] 周兴,易怀红,宋廉.超声弹性成像声触诊组织成像量化指标评估肝血吸虫病患者肝纤维化价值临床研究.实用肝脏病杂志,2022,25(3):399-402
[19] Ng YZ, Lai LL, Wong SW, et al. Attenuation parameter and liver stiffness measurement using fibrotouch vs fibroscan in patients with chronic liver disease. PLoS One, 2021, 16(5):e0250300.
[20] Zeng F, Wang H, Li X. The defining of the reference range of liver stiffness and fat attenuation parameter for healthy Chinese children. Eur J Gastroenterol Hepatol, 2021, 33(11):1394-1399.
[21] 吴一鸣,殷新光,章丽芳,等.弹性诊断仪(Fibroscan)与无创诊断模型在日本SILD患者肝纤维化评估中的比较.中华肝脏病杂志,2020,28(2):163-167.
[22] Fan R, Li G, Yu N, et al. aMAP score and its combination withliver stiffness measurement accurately assess liver fibrosis in chronic hepatitis b patients. Clin Gastroenterol Hepatol, 2023, 21(12):3070-3079.

FibroTouch和声触诊组织量化成像参数评估血吸虫病性肝病患者肝纤维化临床研究^*

FibroTouch and virtual touch tissue quantification parameters in evaluating liver fibrosis in patients with schistosomiasis-induced liver disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张天挺, 许晶, 姜正伟, 嵇卉. 丙酚替诺福韦联合肝爽颗粒治疗慢性乙型肝炎患者疗效及其对肝纤维化指标的影响^*[J]. 实用肝脏病杂志, 2024, 27(6): 820-823.
[2]	周隽, 张忠新, 徐海燕. 可视化瞬时弹性成像与声触诊弹性成像诊断慢性乙型肝炎患者肝纤维化效能比较^*[J]. 实用肝脏病杂志, 2024, 27(6): 832-835.
[3]	武羽, 韩宇星, 徐曼曼, 焦婧然, 杨雪, 段小宛, 陈煜. DRG付费改革背景下慢加急性肝衰竭患者费用盈亏分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 882-886.
[4]	陈思艳, 郭道宁, 邹晓攀, 漆家高. 彩色多普勒超声评估肝硬化门静脉高压症患者TIPS术后支架功能研究^*[J]. 实用肝脏病杂志, 2024, 27(6): 899-902.
[5]	曾旺, 蔡晓曼, 葛尚. 肝内胆管细胞癌与肝细胞癌病灶MRI增强扫描表现差异分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 907-910.
[6]	丹巴玉珍, 程盼. 增强MRI检查诊断HCC价值研究^*[J]. 实用肝脏病杂志, 2024, 27(6): 911-914.
[7]	杨佳欣, 杨紫郡, 陈卫. 双源CT双能量TNC技术图像质量与诊断肝细胞癌效能分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 915-918.
[8]	邓娜, 郑玉凤, 刘旭红, 韩晓兵, 丁碧娇, 曾纬阳, 刘娜红, 黄莹, 陈梅桂. CT动态增强扫描诊断原发性肝癌效能分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 919-922.
[9]	马紫瑶, 王超, 赵珏, 冯赟, 张铭, 梁凯轶. MRI诊断不典型肝脓肿临床应用价值分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 931-934.
[10]	王玲玲, 姚敏, 姚登福. 肝细胞癌进展过程中KLFs异常表达及其检测的临床价值研究进展^*[J]. 实用肝脏病杂志, 2024, 27(6): 953-956.
[11]	韦新焕, 柳雅立, 张晶, 贾继东. 代谢相关性脂肪性肝硬化诊疗进展^*[J]. 实用肝脏病杂志, 2024, 27(5): 641-645.
[12]	杨逸铭, 李晓环, 刘玉品, 欧金龙, 黎胜, 石美凤, 汪印强. FibroScan、MRI-PDFF和FAST评分识别高危非酒精性脂肪性肝炎患者临床应用研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 701-704.
[13]	谢爱萍, 赵景, 蒋祁明, 何秀波. 超声声衰减系数与受控衰减参数联合肝脏硬度检测诊断NAFLD患者NASH发生效能研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 705-708.
[14]	任艳, 孔明, 徐曼曼, 白丽, 陈煜. 瞬时弹性成像技术和无创诊断模型诊断原发性胆汁性胆管炎患者肝纤维化效能研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 725-728.
[15]	信亮亮, 温智. 2D-SWE技术联合FIB-4和血清VEGF水平评估乙型肝炎肝硬化患者食管静脉曲张价值研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 737-740.